FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Merck Discontinues 2 Keytruda Phase 3 Trials

Merck says that on the recommendation of independent data monitoring committees, it is discontinuing a Keytruda lung cancer trial and a cutaneous squa...

latest-news-card-1
Medical Devices

Tandem Updates Apple Mobile Diabetes Pump App

Tandem Diabetes Care says it is recalling an Apple app used with its t:slim insulin pump and replacing it with updated software.

latest-news-card-1
Human Drugs

CDER Creates Internal AI Council

CDER creates a new internal Artificial Intelligence Council to oversee, coordinate, and consolidate all Center AI activities.

latest-news-card-1
Human Drugs

Nuvectis Gets Orphan Status for NXP800

FDA grants Nuvectis Pharma an orphan drug designation for NXP800 and its use in treating ovarian, fallopian tube, and primary peritoneal cancers.

latest-news-card-1
Medical Devices

Renata Expandable Growth Stent OKd for Infants

FDA approves a Renata Medical PMA for its Minima Growth Stent thats intended for treating congenital heart disease in infants and young children.

latest-news-card-1
Federal Register

Exelas Fentanyl Not Withdraw Over Safety/Efficacy

Federal Register notice: FDA determines that Exela Pharma Sciences fentanyl citrate injections, equivalent to 2.5mg/50mL and 5mg/100mL (EQ 0.05 mg bas...

latest-news-card-1
Federal Register

Mirum Pharma Wins Priority Review Voucher

Federal Register notice: FDA announces that it issued Mirum Pharmaceuticals a priority review voucher for its approved rare pediatric disease product ...

latest-news-card-1
Human Drugs

Leqvio Successfully Lowers LDL-C: Study

Novartis says its Leqvio successfully lowered LDL cholesterol as a monotherapy in the Phase 3 V-MONO trial.

latest-news-card-1
Medical Devices

FDA Warns Companies on Unapproved CPAP Cleaners

FDA warns three companies illegally marketing CPAP cleaning/sanitizing devices in the U.S.

latest-news-card-1
Human Drugs

Soleno Therapeutics NDA for Prader-Willi Drug

FDA accepts for priority review a Soleno Therapeutics NDA for DCCR (diazoxide choline) for treating Prader-Willi syndrome (PWS) in individuals aged fo...